UA78500C2 - Amlodipine maleate pharmaceutical composition - Google Patents

Amlodipine maleate pharmaceutical composition Download PDF

Info

Publication number: UA78500C2
Authority: UA; Ukraine
Prior art keywords: specified; amlodipine; composition; oyu; composition according
Prior art date: 2000-12-29

Application number

UA2003077117A

Other languages

English (en)

Ukrainian (uk)

Original Assignee

Pfizer Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-12-29

Filing date

2001-08-15

Publication date

2007-04-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29740874&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA78500(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2001-08-15 Application filed by Pfizer Ltd filed Critical Pfizer Ltd

2007-04-10 Publication of UA78500C2 publication Critical patent/UA78500C2/uk

Links

229960000528 amlodipine Drugs 0.000 title claims abstract description 90
TZNOWAJJWCGILX-BTJKTKAUSA-N (z)-but-2-enedioic acid;3-o-ethyl 5-o-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound OC(=O)\C=C/C(O)=O.CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl TZNOWAJJWCGILX-BTJKTKAUSA-N 0.000 title claims abstract description 59
239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 25
239000002245 particle Substances 0.000 claims abstract description 16
239000000203 mixture Substances 0.000 claims description 86
239000000945 filler Substances 0.000 claims description 36
238000000034 method Methods 0.000 claims description 36
229910000389 calcium phosphate Inorganic materials 0.000 claims description 21
239000002775 capsule Substances 0.000 claims description 19
229920000168 Microcrystalline cellulose Polymers 0.000 claims description 18
229940016286 microcrystalline cellulose Drugs 0.000 claims description 18
235000019813 microcrystalline cellulose Nutrition 0.000 claims description 18
239000008108 microcrystalline cellulose Substances 0.000 claims description 18
239000001506 calcium phosphate Substances 0.000 claims description 14
235000011010 calcium phosphates Nutrition 0.000 claims description 14
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical group [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 14
238000002156 mixing Methods 0.000 claims description 11
206010002383 Angina Pectoris Diseases 0.000 claims description 9
239000003795 chemical substances by application Substances 0.000 claims description 8
239000002552 dosage form Substances 0.000 claims description 8
206010020772 Hypertension Diseases 0.000 claims description 7
239000002253 acid Substances 0.000 claims description 6
239000007787 solid Substances 0.000 claims description 6
206010019280 Heart failures Diseases 0.000 claims description 5
230000002265 prevention Effects 0.000 claims description 5
230000002378 acidificating effect Effects 0.000 claims description 4
238000003825 pressing Methods 0.000 claims description 4
HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 claims description 3
238000011049 filling Methods 0.000 claims description 3
239000012458 free base Substances 0.000 claims description 3
229940126601 medicinal product Drugs 0.000 claims description 3
230000004888 barrier function Effects 0.000 claims description 2
238000005550 wet granulation Methods 0.000 claims description 2
208000024172 Cardiovascular disease Diseases 0.000 claims 2
LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims 2
229910000160 potassium phosphate Inorganic materials 0.000 claims 1
235000011009 potassium phosphates Nutrition 0.000 claims 1
238000012876 topography Methods 0.000 claims 1
239000002002 slurry Substances 0.000 abstract 1
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 37
ZPBWCRDSRKPIDG-UHFFFAOYSA-N amlodipine benzenesulfonate Chemical compound OS(=O)(=O)C1=CC=CC=C1.CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl ZPBWCRDSRKPIDG-UHFFFAOYSA-N 0.000 description 32
235000019359 magnesium stearate Nutrition 0.000 description 23
239000000546 pharmaceutical excipient Substances 0.000 description 14
239000000843 powder Substances 0.000 description 14
238000013112 stability test Methods 0.000 description 14
239000012535 impurity Substances 0.000 description 12
229960004005 amlodipine besylate Drugs 0.000 description 10
235000019691 monocalcium phosphate Nutrition 0.000 description 10
239000000725 suspension Substances 0.000 description 10
239000007900 aqueous suspension Substances 0.000 description 9
YYRMJZQKEFZXMX-UHFFFAOYSA-L calcium bis(dihydrogenphosphate) Chemical group [Ca+2].OP(O)([O-])=O.OP(O)([O-])=O YYRMJZQKEFZXMX-UHFFFAOYSA-L 0.000 description 9
239000000126 substance Substances 0.000 description 9
OWGHROPUZICLBA-DJZRFWRSSA-N (2s)-2-[2-[[4-(2-chlorophenyl)-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl-1,4-dihydropyridin-2-yl]methoxy]ethylamino]butanedioic acid Chemical compound CCOC(=O)C1=C(COCCN[C@@H](CC(O)=O)C(O)=O)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl OWGHROPUZICLBA-DJZRFWRSSA-N 0.000 description 8
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 8
229940079832 sodium starch glycolate Drugs 0.000 description 8
239000008109 sodium starch glycolate Substances 0.000 description 8
229920003109 sodium starch glycolate Polymers 0.000 description 8
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 8
150000003839 salts Chemical class 0.000 description 7
239000000454 talc Substances 0.000 description 7
229910052623 talc Inorganic materials 0.000 description 7
230000015572 biosynthetic process Effects 0.000 description 6
238000003860 storage Methods 0.000 description 6
238000002360 preparation method Methods 0.000 description 5
SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 4
230000000052 comparative effect Effects 0.000 description 4
229940079593 drug Drugs 0.000 description 4
239000003814 drug Substances 0.000 description 4
238000009472 formulation Methods 0.000 description 4
239000007903 gelatin capsule Substances 0.000 description 4
239000000463 material Substances 0.000 description 4
239000007909 solid dosage form Substances 0.000 description 4
101150105088 Dele1 gene Proteins 0.000 description 3
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
239000013543 active substance Substances 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
239000003085 diluting agent Substances 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
239000000314 lubricant Substances 0.000 description 3
239000000395 magnesium oxide Substances 0.000 description 3
CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 3
AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 3
239000011976 maleic acid Substances 0.000 description 3
JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
229940127291 Calcium channel antagonist Drugs 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
229930195725 Mannitol Chemical group 0.000 description 2
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
239000004698 Polyethylene Substances 0.000 description 2
201000001068 Prinzmetal angina Diseases 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
239000002585 base Substances 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
239000000480 calcium channel blocker Substances 0.000 description 2
FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
239000003086 colorant Substances 0.000 description 2
238000000354 decomposition reaction Methods 0.000 description 2
238000011161 development Methods 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
230000000694 effects Effects 0.000 description 2
235000013305 food Nutrition 0.000 description 2
239000008187 granular material Substances 0.000 description 2
238000005469 granulation Methods 0.000 description 2
230000003179 granulation Effects 0.000 description 2
150000004677 hydrates Chemical class 0.000 description 2
239000007788 liquid Substances 0.000 description 2
239000000594 mannitol Chemical group 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
239000005022 packaging material Substances 0.000 description 2
238000012545 processing Methods 0.000 description 2
239000000047 product Substances 0.000 description 2
239000008247 solid mixture Substances 0.000 description 2
239000002904 solvent Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
238000012360 testing method Methods 0.000 description 2
239000005541 ACE inhibitor Substances 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical group O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 description 1
101100130927 Caenorhabditis elegans moa-2 gene Proteins 0.000 description 1
235000010469 Glycine max Nutrition 0.000 description 1
244000068988 Glycine max Species 0.000 description 1
AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
208000001953 Hypotension Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical group OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
238000006845 Michael addition reaction Methods 0.000 description 1
PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
229920001328 Polyvinylidene chloride Polymers 0.000 description 1
RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
208000007718 Stable Angina Diseases 0.000 description 1
208000009325 Variant Angina Pectoris Diseases 0.000 description 1
238000007259 addition reaction Methods 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
239000004004 anti-anginal agent Substances 0.000 description 1
229940124345 antianginal agent Drugs 0.000 description 1
239000002220 antihypertensive agent Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
229960005370 atorvastatin Drugs 0.000 description 1
229960004530 benazepril Drugs 0.000 description 1
229960003619 benazepril hydrochloride Drugs 0.000 description 1
VPSRQEHTHIMDQM-FKLPMGAJSA-N benazepril hydrochloride Chemical compound Cl.C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 VPSRQEHTHIMDQM-FKLPMGAJSA-N 0.000 description 1
229940077388 benzenesulfonate Drugs 0.000 description 1
239000000872 buffer Substances 0.000 description 1
BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 description 1
239000000292 calcium oxide Substances 0.000 description 1
ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000008199 coating composition Substances 0.000 description 1
239000013065 commercial product Substances 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
229960000913 crospovidone Drugs 0.000 description 1
101150038956 cup-4 gene Proteins 0.000 description 1
239000007857 degradation product Substances 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
229940085304 dihydropyridine derivative selective calcium channel blockers with mainly vascular effects Drugs 0.000 description 1
125000004925 dihydropyridyl group Chemical class N1(CC=CC=C1)* 0.000 description 1
238000007907 direct compression Methods 0.000 description 1
201000010099 disease Diseases 0.000 description 1
238000001035 drying Methods 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
230000037406 food intake Effects 0.000 description 1
239000011521 glass Substances 0.000 description 1
208000019622 heart disease Diseases 0.000 description 1
229920001903 high density polyethylene Polymers 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
239000004700 high-density polyethylene Substances 0.000 description 1
239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
208000021822 hypotensive Diseases 0.000 description 1
230000001077 hypotensive effect Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000000302 ischemic effect Effects 0.000 description 1
239000008101 lactose Chemical group 0.000 description 1
229960004844 lovastatin Drugs 0.000 description 1
PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
229940057948 magnesium stearate Drugs 0.000 description 1
150000002688 maleic acid derivatives Chemical class 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
238000004859 neutralization-reionization mass spectrometry Methods 0.000 description 1
238000010606 normalization Methods 0.000 description 1
239000003002 pH adjusting agent Substances 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000004526 pharmaceutical effect Effects 0.000 description 1
239000006187 pill Substances 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000005033 polyvinylidene chloride Substances 0.000 description 1
235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
229940069328 povidone Drugs 0.000 description 1
239000002243 precursor Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000008569 process Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
150000003222 pyridines Chemical class 0.000 description 1
238000003908 quality control method Methods 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
238000007873 sieving Methods 0.000 description 1
229960002855 simvastatin Drugs 0.000 description 1
RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
229940080313 sodium starch Drugs 0.000 description 1
229940045902 sodium stearyl fumarate Drugs 0.000 description 1
239000000243 solution Substances 0.000 description 1
239000012453 solvate Substances 0.000 description 1
241000894007 species Species 0.000 description 1
238000012430 stability testing Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
239000007916 tablet composition Substances 0.000 description 1
239000006068 taste-masking agent Substances 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
230000002861 ventricular Effects 0.000 description 1
238000005406 washing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Cardiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Heart & Thoracic Surgery (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Inorganic Chemistry (AREA)
Organic Chemistry (AREA)
Hospice & Palliative Care (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

UA2003077117A 2000-12-29 2001-08-15 Amlodipine maleate pharmaceutical composition UA78500C2 (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US25856200P	2000-12-29	2000-12-29
US80934601A	2001-03-16	2001-03-16
AT0063401U AT5874U1 (de)	2000-12-29	2001-08-09	Pharmazeutische zubereitungen enthaltend amlodipinmaleat
PCT/NL2001/000606 WO2002053134A1 (fr)	2000-12-29	2001-08-15	Compositions pharmaceutiques contenant du maleate d'amlodipine
BE2001/0706A BE1014449A6 (nl)	2000-12-29	2001-11-05	Farmaceutische verbindingen omvattende amlodipine maleaat.

Publications (1)

Publication Number	Publication Date
UA78500C2 true UA78500C2 (en)	2007-04-10

Family

ID=29740874

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA2003077117A UA78500C2 (en)	2000-12-29	2001-08-15	Amlodipine maleate pharmaceutical composition

Country Status (26)

Country	Link
US (1)	US6919087B2 (fr)
EP (1)	EP1309317B1 (fr)
CN (1)	CN1268322C (fr)
AP (1)	AP2003002819A0 (fr)
AT (3)	AT5874U1 (fr)
AU (1)	AU2001290354B2 (fr)
BE (1)	BE1014449A6 (fr)
BR (1)	BR0116556A (fr)
CA (1)	CA2433035C (fr)
DE (2)	DE60118008T2 (fr)
DK (3)	DK1309317T3 (fr)
EA (1)	EA008101B1 (fr)
ES (1)	ES2258549T3 (fr)
FI (1)	FI6787U1 (fr)
HR (1)	HRP20030527A2 (fr)
IL (1)	IL156691A0 (fr)
IS (1)	IS6833A (fr)
MA (1)	MA26968A1 (fr)
MX (1)	MXPA03005883A (fr)
NO (1)	NO20032517L (fr)
NZ (1)	NZ526505A (fr)
PL (1)	PL362668A1 (fr)
PT (1)	PT1309317E (fr)
RS (1)	RS53303A (fr)
UA (1)	UA78500C2 (fr)
WO (1)	WO2002053134A1 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2002054062A2 (fr) *	2000-12-29	2002-07-11	Pfizer Limited	Standards de reference destines a la determination de la purete ou de la stabilite de maleate d'amlodipine et procedes correspondants
WO2002053540A1 (fr) *	2000-12-29	2002-07-11	Pfizer Limited	Derive aspartate de l'amlodipine utilise comme antagoniste des canaux calciques
US20030027848A1 (en) *	2001-06-15	2003-02-06	Anne Billotte	Stabilized formulations
GB0114709D0 (en) *	2001-06-15	2001-08-08	Pfizer Ltd	Stabilised formulations of amlodipine maleate
US20030180354A1 (en) *	2001-10-17	2003-09-25	Dr. Reddy's Laboratories Limited	Amlodipine maleate formulations
WO2003032954A1 (fr) *	2001-10-17	2003-04-24	Dr. Reddy's Laboratories Ltd.	Formulations pharmaceutiques stabilisees contenant du maleate d'amlodipine
AU2002353659A1 (en) *	2001-12-18	2003-07-15	Synthon B.V.	Simvastatin dosage forms
US20040072879A1 (en) *	2002-10-10	2004-04-15	Dr. Reddy's Laboratories Limited	Crystalline 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl-1,4-dihydropyridine maleate salt (Amlodipine)
DK1435239T3 (da) *	2002-12-31	2006-07-31	Cimex Pharma Ag	Stabiliseret og let forarbejdeligt granulat af amlodipin--maleat
CA2559670A1 (fr) *	2003-04-14	2004-10-28	Gabor Pragai	Formulations ameliorees de maleate d'amlodipine
KR100604034B1 (ko) *	2003-10-08	2006-07-24	주식회사유한양행	암로디핀 유리염기를 함유한 구강 속붕해정 및 그의 조성물
ME01615B (me) *	2004-11-05	2014-09-20	Boehringer Ingelheim Int	Dvoslojna tableta koja sadrži telmisartan i amlodipin
EP1833466A1 (fr) *	2004-12-28	2007-09-19	Ranbaxy Laboratories Limited	Procedes permettant de preparer des formes posologiques pharmaceutiques solides et stables a base d'atorvastatine et d'amlodipine
KR100825039B1 (ko)	2005-01-21	2008-04-24	대원제약주식회사	안정성이 개선된 암로디핀 말레이트염 정제
NZ561486A (en) *	2005-03-15	2011-03-31	Lupin Ltd	Pharmaceutical compositions of amlodipine and benazepril
WO2007020079A2 (fr) *	2005-08-17	2007-02-22	Synthon B.V.	Comprimes de simvastatine a desintegration orale
US8158146B2 (en) *	2005-09-28	2012-04-17	Teva Pharmaceutical Industries Ltd.	Stable combinations of amlodipine besylate and benazepril hydrochloride
AU2005336956A1 (en) *	2005-09-28	2007-04-12	Teva Pharmaceutical Industries Ltd.	Stable combinations of amlodipine besylate and benazepril hydrochloride
DE602005005706T2 (de) *	2005-09-28	2009-04-16	Teva Pharmaceutical Industries Ltd.	Stabile Arzneimittelkombinationen von Amlodipinbesylat und Benazeprilhydrochlorid
KR100689862B1 (ko)	2005-10-04	2007-03-09	삼익제약주식회사	말레인산암로디핀을 포함하는 조성물 및 그의 제조 방법
KR100795313B1 (ko)	2006-09-05	2008-01-21	현대약품 주식회사	암로디핀 베실레이트를 포함하는 약학 조성물
CN101161241B (zh) *	2006-10-10	2010-05-26	扬子江药业集团上海海尼药业有限公司	苯磺酸氨氯地平片的制备工艺
WO2008065485A2 (fr) *	2006-10-19	2008-06-05	Torrent Pharmaceuticals Limited	Compositions pharmaceutiques stables composées d'un bloqueur des canaux calcium et d'un inhibiteur ace
AR064501A1 (es) *	2006-12-22	2009-04-08	Genentech Inc	Antagonistas del dr6 (receptor de muerte 6) y usos de los mismos en el tratamiento de trastornos neurologicos
HU230877B1 (hu) *	2008-09-30	2018-11-29	EGIS Gyógyszergyár NyR	Stabil kombinációs gyógyszerkészítmény
MA33056B1 (fr)	2009-01-23	2012-02-01	Hanmi Holding Co Ltd	Composition pharmaceutique solide comprenant de l'amlodipine et du losartan et son procede de fabrication
TWI461213B (zh) *	2009-11-05	2014-11-21	Fmc Corp	作為藥物賦形劑之微晶纖維素及磷酸鈣之組合物
CN103054862B (zh) *	2013-01-08	2014-09-17	江苏万高药业有限公司	一种含有马来酸氨氯地平的快速释放的口服固体制剂
EP3960158B1 (fr)	2016-10-07	2025-05-21	Silvergate Pharmaceuticals, Inc.	Formulations d'amlodipine
WO2019200143A1 (fr)	2018-04-11	2019-10-17	Silvergate Pharmaceuticals, Inc.	Formulations d'amlodipine
CN111728948A (zh) *	2020-08-19	2020-10-02	湖北潜龙药业有限公司	一种苯磺酸氨氯地平片的制备工艺

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK161312C (da)	1982-03-11	1991-12-09	Pfizer	Analogifremgangsmaade til fremstilling af 2-aminoalkoxymethyl-4-phenyl-6-methyl-1,4-dihydropyridin-3,5-dicarboxylsyreestere eller syreadditionssalte deraf samt phthalimidoderivater til anvendelse som udgangsmateriale ved fremgangsmaaden
GB8306666D0 (en)	1983-03-10	1983-04-13	Pfizer Ltd	Therapeutic agents
US4687662A (en) *	1985-08-30	1987-08-18	Warner-Lambert Company	Therapeutic effervescent composition
GB8608335D0 (en)	1986-04-04	1986-05-08	Pfizer Ltd	Pharmaceutically acceptable salts
US4983740A (en)	1986-08-04	1991-01-08	Adir Et Compagnie	Process for 1,4-dihydropyridine compounds
GB8710493D0 (en)	1987-05-02	1987-06-03	Pfizer Ltd	Dihydropyridines
US5155120A (en)	1991-01-14	1992-10-13	Pfizer Inc	Method for treating congestive heart failure
WO1993006082A1 (fr)	1991-09-13	1993-04-01	Merck & Co., Inc.	Procede de preparation de 1,4-dihyropyridines-4-substitues
US6057344A (en)	1991-11-26	2000-05-02	Sepracor, Inc.	Methods for treating hypertension, and angina using optically pure (-) amlodipine
EP1013275A3 (fr) *	1991-11-26	2001-01-10	Sepracor, Inc.	Procédés et compositions destinés à traiter l'hypertension, l'angine de poitrine et d'autres troubles à l'aide de (-) amlodipine optiquement pure
AT399718B (de) *	1992-04-16	1995-07-25	Lek Tovarna Farmacevtskih	Inklusionskomplexe von optisch aktiven und racemischen 1,4-dihydropyridinen mit methyl-beta- cyclodextrin oder anderen cyclodextrinderivaten, ein verfahren zur herstellung von optisch aktiven dihydropyridinen und deren inklusionskomplexen und diese komplexe enthaltende pharmazeutische formulierungen
US5389654A (en)	1992-11-26	1995-02-14	Lek, Tovarna, Farmacevtskih In Kemicnih . . .	3-ethyl 5-methyl(±)2-[2-(N-tritylamino)ethoxymethyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-6-methyl-3,5-pyridinedicarboxylate
GB9317773D0 (en) *	1993-08-26	1993-10-13	Pfizer Ltd	Therapeutic compound
WO1995034299A1 (fr) *	1994-06-10	1995-12-21	Telor Ophthalmic Pharmaceuticals, Inc.	Inhibition du myosis/de la production de mydriase peroperatoire par des agents bloquant les canaux calciques
US5585115A (en) *	1995-01-09	1996-12-17	Edward H. Mendell Co., Inc.	Pharmaceutical excipient having improved compressability
HU222497B1 (hu) *	1996-12-18	2003-07-28	Chinoin Gyógyszer és Vegyészeti Termékek Gyára Rt.	Enalapril-maleátot tartalmazó stabilizált gyógyszerkészítmény és eljárás előállítására
HU221810B1 (hu)	1997-08-12	2003-01-28	EGIS Gyógyszergyár Rt.	Eljárás amlodipin-bezilát előállítására és az eljárás intermedierjei
ZA9810320B (en)	1997-11-14	2000-05-11	Gea Farmaceutisk Fabrik As	Process for the preparation of 1,4-dihydropyridines and novel compounds of use for such purpose.
PL189666B1 (pl)	1998-04-09	2005-09-30	Adamed Sp Z Oo	Sposób otrzymywania benzenosulfonianu amlodypiny
JP3719874B2 (ja) *	1998-04-24	2005-11-24	サンスター株式会社	口腔用組成物
GB9812413D0 (en)	1998-06-10	1998-08-05	Glaxo Group Ltd	Compound and its use
ES2151850B1 (es)	1998-10-26	2001-08-16	Esteve Quimica Sa	Intermedio para la sintesis de amlodipino para su obtencion y utilizacion correspondiente.
GB9827431D0 (en)	1998-12-11	1999-02-03	Smithkline Beecham Plc	Novel compound
GB9827387D0 (en)	1998-12-11	1999-02-03	Smithkline Beecham Plc	Novel process
GB0008332D0 (en) *	2000-04-04	2000-05-24	Pfizer Ltd	Treament
GB0020842D0 (en) *	2000-08-23	2000-10-11	Pfizer Ltd	Therapeutic compositions

2001
- 2001-08-09 AT AT0063401U patent/AT5874U1/de not_active IP Right Cessation
- 2001-08-15 PT PT01970353T patent/PT1309317E/pt unknown
- 2001-08-15 ES ES01970353T patent/ES2258549T3/es not_active Expired - Lifetime
- 2001-08-15 UA UA2003077117A patent/UA78500C2/uk unknown
- 2001-08-15 AU AU2001290354A patent/AU2001290354B2/en not_active Ceased
- 2001-08-15 IL IL15669101A patent/IL156691A0/xx unknown
- 2001-08-15 EP EP01970353A patent/EP1309317B1/fr not_active Expired - Lifetime
- 2001-08-15 HR HR20030527A patent/HRP20030527A2/hr not_active Application Discontinuation
- 2001-08-15 MX MXPA03005883A patent/MXPA03005883A/es active IP Right Grant
- 2001-08-15 EA EA200300740A patent/EA008101B1/ru not_active IP Right Cessation
- 2001-08-15 AP APAP/P/2003/002819A patent/AP2003002819A0/en unknown
- 2001-08-15 DE DE60118008T patent/DE60118008T2/de not_active Expired - Fee Related
- 2001-08-15 CA CA002433035A patent/CA2433035C/fr not_active Expired - Fee Related
- 2001-08-15 CN CNB018216692A patent/CN1268322C/zh not_active Expired - Fee Related
- 2001-08-15 BR BR0116556-9A patent/BR0116556A/pt not_active IP Right Cessation
- 2001-08-15 DK DK01970353T patent/DK1309317T3/da active
- 2001-08-15 NZ NZ526505A patent/NZ526505A/en unknown
- 2001-08-15 PL PL01362668A patent/PL362668A1/xx not_active Application Discontinuation
- 2001-08-15 WO PCT/NL2001/000606 patent/WO2002053134A1/fr not_active Ceased
- 2001-08-15 AT AT01970353T patent/ATE320244T1/de not_active IP Right Cessation
- 2001-08-15 RS YU53303A patent/RS53303A/sr unknown
- 2001-08-27 US US09/938,816 patent/US6919087B2/en not_active Expired - Fee Related
- 2001-10-08 DE DE20116428U patent/DE20116428U1/de not_active Ceased
- 2001-11-05 BE BE2001/0706A patent/BE1014449A6/nl not_active IP Right Cessation
2003
- 2003-05-26 MA MA27179A patent/MA26968A1/fr unknown
- 2003-05-30 IS IS6833A patent/IS6833A/is unknown
- 2003-06-04 NO NO20032517A patent/NO20032517L/no not_active Application Discontinuation
- 2003-12-12 DK DK200300347U patent/DK200300347U3/da not_active IP Right Cessation
- 2003-12-12 DK DK200300346U patent/DK200300346U4/da not_active IP Right Cessation
- 2003-12-17 FI FI20030475U patent/FI6787U1/fi active IP Right Grant
- 2003-12-29 AT AT0093303U patent/AT7729U3/de not_active IP Right Cessation

Also Published As

Publication number	Publication date
NZ526505A (en)	2005-04-29
US20020176889A1 (en)	2002-11-28
AT5874U1 (de)	2003-01-27
DK200300346U1 (da)	2003-12-12
DE60118008D1 (de)	2006-05-11
NO20032517L (no)	2003-06-20
AU2001290354B2 (en)	2006-09-21
US6919087B2 (en)	2005-07-19
PL362668A1 (en)	2004-11-02
AP2003002819A0 (en)	2003-06-30
AT7729U3 (de)	2006-01-15
NO20032517D0 (no)	2003-06-04
FIU20030475U0 (fi)	2003-12-17
BE1014449A6 (nl)	2003-10-07
CN1268322C (zh)	2006-08-09
HRP20030527A2 (en)	2005-06-30
DE20116428U1 (de)	2002-01-10
IS6833A (is)	2003-05-30
EA008101B1 (ru)	2007-04-27
FI6787U1 (fi)	2005-09-14
HK1064601A1 (en)	2005-02-04
CN1486176A (zh)	2004-03-31
IL156691A0 (en)	2004-01-04
CA2433035A1 (fr)	2002-07-11
HK1055904A1 (en)	2004-01-30
BR0116556A (pt)	2004-02-17
MXPA03005883A (es)	2005-04-19
AT7729U2 (de)	2005-08-25
DK200300346U4 (da)	2004-04-23
ES2258549T3 (es)	2006-09-01
CA2433035C (fr)	2006-04-25
WO2002053134A1 (fr)	2002-07-11
EP1309317B1 (fr)	2006-03-15
ATE320244T1 (de)	2006-04-15
DE60118008T2 (de)	2006-10-26
MA26968A1 (fr)	2004-12-20
EA200300740A1 (ru)	2003-10-30
DK200300347U3 (da)	2004-03-12
EP1309317A1 (fr)	2003-05-14
PT1309317E (pt)	2006-06-30
RS53303A (sr)	2006-10-27
DK1309317T3 (da)	2006-06-19

Publication	Publication Date	Title
UA78500C2 (en)	2007-04-10	Amlodipine maleate pharmaceutical composition
AU2001290354A1 (en)	2003-01-23	Pharmaceutical compositions comprising amlodipine maleate
HUP0303827A2 (hu)	2004-04-28	Paroxetinkészítmények és eljárások ezek előállítására
JPH03500288A (ja)	1991-01-24	徐放性ニフェジピン製剤
JP6476331B2 (ja)	2019-02-27	イソニアジドの顆粒およびリファペンチンの顆粒を含む分散性錠剤の形態の抗結核性の安定な医薬組成物ならびにその製造方法
EP1833466A1 (fr)	2007-09-19	Procedes permettant de preparer des formes posologiques pharmaceutiques solides et stables a base d'atorvastatine et d'amlodipine
JP2023502011A (ja)	2023-01-20	レバムロジピンベシル酸塩水和物含有組成物及びその調製方法
AU741201B2 (en)	2001-11-22	8-chloro-6,11-dihydro-11-(4-piperidylidene)-5H-benzo(5,6) cyclohepta (1,2-b)pyridine oral compositions
EP1615642A1 (fr)	2006-01-18	Combinaison de paroxetine et de 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2s-phenyl-piperidin-3s-yl)-amine dans le traitement de la depression et/ou de l'anxiete
WO2008149201A2 (fr)	2008-12-11	Composition pharmaceutique stable
RU2188018C2 (ru)	2002-08-27	Композиционный состав антибактериального лекарственного средства
CZ20031899A3 (en)	2004-03-17	Pharmaceutical tablet comprising paroxetine mesylate
EA027787B1 (ru)	2017-09-29	Пероральные лекарственные формы, содержащие лерканидипин и эналаприл и их фармацевтически приемлемые соли
AU2001100431A4 (en)	2001-11-01	Pharmaceutical compositions comprising amlodipine maleate
KR20030070594A (ko)	2003-08-30	암로디핀 말레에이트를 포함하는 약학 조성물
JPS6045162B2 (ja)	1985-10-08	抗抑うつ症剤
SI21062A2 (sl)	2003-04-30	Farmacevtski sestavki, ki obsegajo amlodipin maleat
US20240285618A1 (en)	2024-08-29	Pharmaceutical compositions of lumateperone
EA046741B1 (ru)	2024-04-17	СТАБИЛЬНЫЕ, ПРИГОТОВЛЕННЫЕ В ФОРМЕ ТАБЛЕТОК И КАПСУЛ, КОМПОЗИЦИИ С НЕМЕДЛЕННЫМ ВЫСВОБОЖДЕНИЕМ 1-((2S,5R)-5-((7H-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)АМИНО)-2-МЕТИЛПИПЕРИДИН-1-ИЛ)ПРОП-2-ЕН-1-ОНА
NL1018755C1 (nl)	2001-11-02	Farmaceutische verbindingen omvattende amlodipine maleaat.
HK1055904B (en)	2006-08-18	Pharmaceutical compositions comprising amlodipine maleate
HK40070723B (zh)	2024-12-06	1-((2s，5r)-5-((7h-吡咯并[2，3-d]嘧啶-4-基)氨基)-2-甲基哌啶-1-基)丙-2-烯-1-酮的稳定立即释放片剂和胶囊制剂
CZ12025U1 (cs)	2002-03-04	Farmaceutické prostředky obsahující amlodipinmaleát a jejich použití
CA3166050A1 (fr)	2021-07-08	Formulations stables de capsules et comprimes a liberation immediate de 1-((2s,5r)-5-((7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one
HK40070723A (en)	2022-10-28	Stable immediate release tablet and capsule formulations of 1-((2s,5r)-5-((7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one